Specialty Carveout Drug Programs and what they mean for Oncology Patients and Support Access

Dawn Holcombe, MBA, FACMPE, ACHE

President, DGH Consulting

President, National Oncology State Network

Editor in Chief, Journal of Oncology Practice Management

Iowa Oncology Society 03/10/2023

Agenda

- Why Self Insured Employers Challenges for Benefits Management
- How Specialty Capture/Alternative Funding Sources
- Who and What Players and Their Pitch
- Impact Adverse Consequences: Real and Potential
- Plan of Action for Change

Self Insured Employers Challenges for Benefits Management Why?

Self-Insured Employers Are Worried

NAHPC

-Top 10 most expensive US drugs – over \$630,000 to over \$2 million annually

-Growing specialty drugs and biosimilars in pipeline

Specialty Medicines are nearly
50% of a plan's total drug spend

- About 35% of those are in Medical Benefits

National Alliance of healthcare Purchaser Coalitions 2021 Annual Report - file:///C:/Users/User/Downloads/NA%20Annual%20Report 2021 FNL2.p



Target: High-Cost Claims

Rethinking How We Mitigate HIGH-COST CLAIMS

The Problem: Few (if any) employers have the size, resources or focus to address rapidly escalating high-cost claims. Since 2016, the number of health plan members with claims \$3M+ has doubled, heightening sustainability concerns. Elimination of annual and lifetime maximums through the Affordable Care Act and the dysfunction of the reinsurance market has made this a top priority for every employer, purchaser and market.

High-Cost Claims Defined:

- Unpredictable/infrequent for individual employers
- Claims costing \$50,000 or more per year
- · Cost outliers that are frequently lasered (i.e., stoploss insurance covers only the first year of claims, then will cover everything except that claim)
- Often for severe, debilitating disease conditions



DGH Consulting - CONFIDENTIAL

5

NAHPC Strategies to Reduce Drug Costs

Be Proactive, not Reactive

Specific Saving Strategies for High-Cost Medical Drugs Learn more: <u>Achieving Accountability & Predictibility on the Medical Side of Drug Benefits</u>

CLINICAL RIGOR

- Separation of dispensing/rebates from clinical functions
- Independent, expert clinical management
- Cost-effective step therapy, when appropriate
- Elimination of waste
- Same level of clinical rigor applied to to specialty drugs on medical side
- Longer term increased specialization

Contracting Strategies

- Deconflict PBM and medical carrier relationships (fiduciary compliant)
- Reduced/fixed markups for provider buy/bill drugs
- Outcomes-based drug pricing
 Specialty generics filled in retail,
- not at specialty pharmacy - Payment amortization (pay-over-time)
- Hospital at home/telehealth
- Narrow networks
- More timely and transparent reporting
- Bill review/negotiation
- Longer term population-based hybrid contracts

COST-EFFECTIVE SOURCING

- Better align co-pay and patient assistance programs
- Unrestricted, competitive dispensing options and sources

Plan Design Strategies

Quantity limits

Specialty carve out

Step therapy

high-cost drugs

 Site-of-care optimization for provideradministered drugs

Dose rounding protocols (for injectables)

More rigorous utilization management for

PA/pre-certification functions

Preferred drug lists/formularies

Exclusions/coverage limitations

Longer term - Steerage to improve quality,

Leverage secondary coverage when available

Aligned financial incentives with plan participants

(e.g., spouse employer, Medicaid or Medicare)


appropriateness and reduce impact of middlemen

 Longer term – collective management & stewardship

All drug management under the pharmacy benefit

Integrate Core Pillars of Overall Risk and Cost Reduction

There is no one-size-fits-all approach to tackle the broad spectrum of high-cost claims; a combination of options is needed for each case







National Alliance of Healthcare Purchaser Coalitions | 1015 18th Street, NW, Suite 705 Washington, DC 20036 | (202) 775-9300 | nationalalliancehealth.org |twitter.com/ntlalliancehth | linkedin.com/company/national-alliance/

3/10/2023

DGH Consulting - CONFIDENTIAL

6

06/21


Specialty Capture/Alternative Funding Sources Where?

What are the "Specialty"/Alternate" Funds/Sources?

Manufacturer Programs • Free-Drug • Copay Assistance Programs (CAPS)	Foundations	Patient Advocacy Groups
Brownbagged, Whitebagged Drugs	Importations from Canada and overseas (India, Australia)	Other?

Will you see these?

- Maybe not.
- They contract directly with self-insured employers.
- They are often recommended by brokers as a cost saving mechanism.
- They contact patients directly to enroll in their programs, and have patients sign over medical and financial information and details, including prescriptions.
- Patients just may come to providers and inform them they are not covered, or have to receive drug from another source or face significant penalties.



The Major Issues

- Self declaration that specific specialty drugs are not protected as essential health benefits, and therefore fair game for targeting coverage and patient financial obligation changes
- Tell the self-insured employer, union, etc. that **they can obtain alternative funding** so that specialty pharmacy costs are sharply decreased
- Claim that **only a small percentage of employees** are affected, so will be **easy to achieve large savings with small impact**
- Increase demand on patient assistance programs, free drug, charity, foundations for already limited resources
- Engage in wholesale importation of drugs from outside the US with no pedigree and no liability for resultant medical issues
- Coerce and confuse vulnerable patients, disrupt care, insert delays, bait and switch coverage, and add cost to medical system without adding value

"Non-Essential Benefit" Declaration

- Patient Protection and Affordable Care Act (ACA) essential health benefit (EHB)
 - Requires individual and small group markets to cover 10 essential health benefits including ambulatory patient services, prescription drugs, and preventive and wellness services and chronic disease management.
 - <u>https://www.cms.gov/cciio/resources/data-resources/ehb</u>
- Specialty carveout vendors improperly designates one or more specialty medications as a "non-essential" health benefit, and therefore not subject to the ACAs EHB limits on consumers' annual out of pocket costs
 - Vendor then charges patients copays equal to the full amount of copay assistance available through the manufacturer copay assistance program
 - AND refuses to count the medication copays toward the consumers' annual deductible and annual out-of-pocket costs

New Employer Fiduciary Responsibility

- The Consolidated Appropriations Act, 2021 (CAA) established protections for consumers related to surprise billing and transparency in health care <u>https://www.cms.gov/cciio/programs-and-initiatives/other-insurance-protections/caa</u>
- Self insured employers are required to ensure their group health plan is cost-effective, offers quality care, and meets new mental health parity and pharmacy benefit requirements contained in the CAA.
- CMS letter to Illinois re enforcement of the CCA clarifying where the state and CMS will hold enforcement responsibility <u>https://www.cms.gov/files/document/caa-enforcement-letters-illinois.pdf</u>
- The Summary of Material Modification (SMM) apprises participants and beneficiaries of changes made to the plan or to the information required to be in the SPD. The SMM or an updated SPD for a group health plan must be furnished automatically to participants not later than 210 days after the end of the plan year in which the change was adopted. If the change is a material reduction in covered services or benefits, the plan administrator must furnish the SMM within 60 days after the reduction is adopted. A material reduction is any plan change that: Eliminates benefits, Reduces benefits payable, Increases premiums, deductibles, coinsurance or co-payments, Reduces the service area an HMO covers, or Establishes new conditions or requirements (such as pre-authorization) for obtaining services or benefits.
- <u>https://www.dol.gov/sites/dolgov/files/ebsa/about-ebsa/our-activities/resource-</u> <u>center/publications/understanding-your-fiduciary-responsibilities-under-a-group-health-plan.pdf</u>
- Lawsuits are already appearing from employees and employee representatives challenging their employers for failure to act in the employee's best interests in decisions and transparency related to the group health benefits.

Players and Their Pitch Who?

A Growing Market Niche – saving \$ for Employers

- Third Party Vendors
 - ImpaxRx <u>www.impaxrx.com</u> (Prescription Advocates)
 - PaydHealth <u>www.paydhealth.com</u> (Advocacy Service)
 - PayerMatrix <u>www.payermatrix.com</u> (Clinical Care Management, Specialty Drug Advocacy)
 - RxFree4me <u>www.Rxfree4me.com</u> (Pharmacy Consulting Company)
 - SHARx <u>www.sharxplan.com</u>
 - SavOnSP <u>www.saveonSP.com</u> (Plan Participant-Focused Cost Saving Services)
 - ScriptSourcing <u>www.scriptsourcing.com</u> (Saving People Money on Name Brand Medications)
 - And at least 14 more.....

ImpaxRx, Boca Raton, FL

Fully insured employers receive no transparency. Hidden costs bundled in medical and pharmacy benefits.

Alternate Distribution Channels to help individuals qualify for MUM[™] solutions

"No More Copays for qualifying employees"

Medications delivered to patient home or prescribing MD offices

Once the employer engages with ImpaxRX MUM[™] the employee must participate in the process by providing all the documentation and information to ImpaxRX[™] in order to use the benefits.

CA hospital, 28 employees qualified out of 370. 17 high cost specialty medications, 1 short duration. Added 2 more employees and 4 more drugs during the year \$622K savings to date

PA charter school, 15 employees qualified out of 418. 11 high cost specialty medications. Added 5 more employees and 4 more drugs during the year. \$696K savings to date.

PaydHealth, Dallas TX

- Empathetic Savings, Alternate Funding Solutions, Prescription Benefit, Medical Benefit
- Many Drug Manufacturer Programs to get reduced or no cost to the employee
- Team will secure funding for medication not covered under insurance plan
- Health Plan denies drug, sends to PaydHealth (CareFactor). Letter and FAQ sent to employee, 30 days to complete applications including household size and income. Drug card used in the interim during securing funding. If approved, employee receives free drug from manufacturer (usually for 6 to 12 months). If partial funding approved, SP (Magellan) fills the script. Partial funding used as member responsibility so zero pay. If doesn't qualify, script goes back to SP and processed under the plan prescription benefit.
- Magellan, city employees, unions, trust funds,
- "Plan requires employees to enroll in the Specialty Healthcare Advocacy Program" If you do not, Coinsurance or Out of Pocket costs will be 100% of pharmacy billed charges and not apply to annual maximum amount or deductible"
- If not eligible for identified alternate funding, case will be automatically submitted for benefit reconsideration under the Plan
- All specialty drugs paid for by plan must be distributed by _____Specialty Pharmacy

PaydHealth Select Drugs and Products[™] List 1/1/22 Page 1 https://www.neca-ibew.org/PaydHealth

Effective lanuary 1, 2022 - Healthcare practitioner-administered in italics

Service of the servic

WYCHOR:

Short Editory

Plant course believes be

Paydhealth

Advenergic Vesepressor Agents Northern Advene corticotrophic Hermones Amonto To Tooget Multiple Sciences the strength large Avenue. Parc Oeterenor and the second sec Realized at Part Carrier Exception Peter protection Continue Charge of the second Contraction of the second s Read of South Statements When the second second Zassain Pieanormuscalar Transmissic Potassium Channel Blockey Anna provide Arring dyceside Artible to And Kally Lake Charter Sector Koltas to Az Photo Tester Fact Storeman A more que ia limitai ta es Rany isc til Arryloider Suppressio its Agents -Transtitive Tencourse A myetrophic Lateral Scienceis Apento Planchicsoner cs, Nesanonal - Calicium A malgestics, Nesarc Chammel Blockers and the second second second Selective Betinoid X Receptor Agonists The second second line Anti-CD20 [8 Lymphoxyte) Publicar second likes All she was a Gazywa Ph/200.00000 Phila month Hereita Auti-Inflammatory In Receptor Antagonist tory interviewicin-1. 100 m mm m m

Enclored (pair Servers) Hours into (la V Servers) Angliescons Resen ic and is Servers) Simpoon' Simpoon' Simpoon' Servers Servers

Anti-Influenceatory Turner Necresis Factor Inhibitor

Access

Circle alice

Select Drugs and Products³⁴⁴ List

Synthesis Inhibitor Annon Anto-Inflammatory, Phasphodinemas-durbibitors Cools Anti-Nerosheyy, Anti-Calapiera

Sector Sec Type Agent Synam Agent Arc-Obseiny - Melanocartin d Beseptor Agentits Arc Jones Arc Jones

And Programmed Cell De Ligend 3 Monoclonel Recentric And bacterial Monoclonel And bacterial Monoclonel

Singhone Anni bioti c Anni anog beri ca

Bhearny oin 3's fate Malator Antifibrine lytic Agents

Riomop Estrict Artithemophilic Pactors Advoce Advocete

Afteryria Alphanate Electote

Experience Parton NP Hermofil M Hormofil M Hormofil M

stur Koase Kogenolef5 Kovalty Novaelght

Monutania Monita March 19 Control to 19 Antihypedipidemic - Anglopeletin-Like 3 Inhibitor Antihyperlipidemic - MTP Inhibitor design in the set of Antifepeotics The lore id All timesoplastic - WEGF Inhibitor Recombinent, Antilbady Alternative inter-44444 2 months and fastic Historye Deacetylese EHICHACT Inshills itoons When her so will soon Parychair. 206028 Antineoplastic - Alkylating Agents -----Sec. Sec. C large the 1-Ryschrotecte Termentar Transmission Water and writing Carponent or Autionoplastic - Auti-CD28 Micensol: Jonal Antii b Contraction for the Charge Mark Francisco Services Approx lastic - Antiandroganis P - Louis da Pail and row Nonemali *----Contraction of the local sectors of the local secto Autioecolastic - Antimetabolites Longurf CONTRACTOR Physical second Victoria and March model and An three op Appendix - Amormaticase -----Announce as soint Antineoplastic - BRAF Kinase I see the state of the second Read to a vi Turk = 1.00

Del boor of Antineoplastic - CAR-T Cell line any any other agong Texamus (all Sorread Antineopletic - Epothilones and Analogs for sector spaces Anti neopłasti s - Hedgehog Patha Inhi bitor Erri conchere Circleron and Antine ophettic - Janua Kinase (JAK) Jackson Th Avoti ne o pilasti c Kima e imini bito Sc - MERS and MERS Contraction Concelluge Suffragile 2 month Antine oplastic - Microtubule Intelligi de attoche pa Holisteen. Antine-oplastic - INITOR Kisase Inshit to ito or o All a stoor (a 5 forward) 70000 Antineophotic - Protein Methyltamolonase Inhibit Taxayerik Antineepkotic - Topolsemenase I Here and the second second second Antineeplastic-VEGF-A, 8-and PLGF lehibitoes 2011100 Antine oplastic - Vinca Alkaloids Stationers in the second Antine oplastic Combinatio Kinase and Argenetace Inhibitor Klogeli Pernare Co-Peck Antine-ophetic EGF Recepto Blocker Monsockenal Antibedy Erich Tann A factor concerned and Manual Inc. Multiple A REAL PROPERTY AND A REAL PROPERTY. Algorith Science (Device) Destructions Plano (and co 70 contrainer as Informed Total Contents Artimeneteris Immunorendulater Aug 10 10 10 10 Page in true Report from Add Promoti yest: Antone opticatic LHEH (CREEK) Antoniot, Pituitary Suppressio

Suppositive LA

Triptodur ALMORTH All used for the Any washing Discourse in the Service income Cascolation CONTRACTOR Eastering income Ceveto GROUP C here at I for a more I cd w stim I make a second Londow Table I THE REPORT INCOMPANY. When we had La moderna Lorbrenz Lympiones Prime Prystance Print sectors and Philod and the Prevente augura Contraction of the local distance of the loc Roatytonek The strength of the Rydapt Course to be Sprycel Stivette Douter th Tables Tegriscov TERRORY Taniance Talente With the second second Marcannia Votrient Xad koort Xons parce Zie (wither

21 yocheol ing

Zirk and her

Finneagen Antineoplastic Systemic Enzyme I miltrid to a s Calcoretect Celigiuence

© 2022 Paydhealth, LLC - All Rights Reserved.

PaydHealth Select Drugs and Products[™] List 1/1/22 Page 2 https://www.neca-ibew.org/PaydHealth

Angle inve Mase pressins (AMP) Receptor Antagoniza

Effective January 1, 2022 - Healthcare practitioner administered in italics

Average and the second

Paydhealth

Astimophatic-CD22 Astibudy Cytotoxic Antibiotic Governmogrand Liquid Charles of the second second Antirecoplastic-8-Cell Lymphorma-2[8C1-2] Inhibiture Venclesces (all forms) and a second sec Antirepoplestic-CD15 Dir. Car-TCell Increase therapy Address of the local data and provide the later Contra a series A REAL PROPERTY OF A REAL PROPER Part Parts As three oplastic bood trate Delrydroge nace 1 minibilor and the second second 1.000 Water of the second second Astineoplastic, Asti-Programmed Death-1 (PD-1) Mab -April Inc. Contractory of the second P rescolation Astineoplastics Astibody/ Astibody-Grug Complexes President all and the second second Compath Charles Contract Charley yes later Transmitted at and the second second attaches and at Carlos I - secondo The second second second -Antireoplastics, Miscellaneous THEFT -----E and the second second Sectors Asti-inflammatory, Sel. Costins. Mod., T-Cellishibitor -Channelies (all formal) Antipoportatic Agents, Syst In the second second Course type Soill forward -2.00 2.000 Table and Dama Tentra (letti Sorrona) Sectored annuals The second diversity of P the North Astinetroviral - Anti-CDE Demain 2 Monoclonal Ab The second line of Tragates Astinetrovical-brograss bobibi and MWETI Corella. And some Down to the local Astinetrusial-integrase inhibitor and NRTI Comb. Ci a grand in the second Antinetrovical-MRTE and Integrate Inhibitors Comb K as here as T + 10,000 mm mm As the structure without bload were Named as a ticket, Proctosators Invalidati dan sera Segment to a set Environment and Lauran Automa Non------and the second second second Course Woorks Chable gamme a Crit © 2022 Paydhealth, LLC - All Rights Reserved.

Samemagand 5-0 Concernance and -----George and an and a second Antonio alla Contra for statistic and a set for Supress, Macora Preparation Protosove Imhibitor Antivirals, HIV-Spec, Nucleoside Neuro Levonti di el Alexandro di Antivirals, HPV Spec., Next worlde Analog, RTI Comb Antivirals, HV Specific, CCRS Co-Receptor Antagonist Antivitals, HIV-Specific, CO6 distance in the second state in the second Applicates, MPA Searcher, Eastern Antiviral to HIV Specific, Noncoldina, WT1 With some sum as 2005 Antivitals, HIV-Specific, Nucleoside Analog, RTI Anthritista, HIV-Specific, Protease Inhibitor Comb Antivirals, HW-Specific, Proteios Antivirals, HPV-1 Integrase Stow Transfer Inhibitor to a service of the second second to the Da

Select Drugs and Products²⁴⁴ List

ALC: V Marchen si di e , Neuc levortiche, Norr-Placia aside PITI Comit Accri p tax Corrections Charles for the second Collections the becould as . Now have take With ALC: NO. OF ALC: NO. State and state of the state of 100 5 T 1 1 1 1 1 1 1 1 Electron - C. and T. and M. Di be Saltz Chool Basers Bone Fermation Stim. Agents -Parathwraid Homesee Concernance. ----etion Stimuleting Agents PTH Red Pegtides There is a Planet Plan proteine induitor torra ALC: NO. 10. inadipleirs = 2 Receptor C1.Externore inhibition -----Plant and state CXCR4 Chamokine Receptor ALC: N DOM: NO. Part and the set Cystic Fib-Transmembrane Conduct, Reg. [CFTR]Popertiator Hall yickeepo Cystic Fibrosis-CPTR Pola Contract and the second second Summer and states To share the set Cystine Depieting Agenta Nephropathic Cystinesis Cystagor Process and Cytechnome PESCIPHIBITORS Tydocost statesic T-Cymphocyte Antigen ECTLA-4] RIVIC Astribucky Orago To Treat Erectile Dysfunction discrimination of the second second

1.00 Or the diling Dyugs to Treat Mexercent DR and the state -----Improvement (and I from mail) The second sector and Drugs to Tx Gase her Dx-Type 1, Schwingt Birch street Conception inter-Carry M. Coccili Pactor IR Complex (PCC) Preparations Advanture State Place Street and Factor IX Preparations Renaution State Ache Number 10.0 An and the second All includes the second Fector X Properation Congents Factor XIII Preparations Concentration of the The same Fibroblast Growth Pactor 23 (FGR22) Inhibitors, Mat Company and Gastric Dracywas Second and the second Genrie Therapy Agents - Shifti Protein Deficiency Zonig workers Derived a Dy¹O Tx - Shift Profesim Deficiency Treatment Everyco di i -----Antisense Oligonus kesi de Example algorithm of all In the International States Growth Hermonie Receptor Antagonists Second an and the Herneghillie Treatment Agents, Non-Factor Replacement Hep-C - NSSA, NSS/4A, No Nucleo, NGSb Inhibitor Care Wheels in an Phale. Hep C Virus-MSS8 Pelymenase and MSS6 Johnshitter Consideration Record Rooms -----

Drugs to Treat Heneditary

Hep-C Mires, Nucleatifie Analog RSSA Polymerase Inhibitor Second dis Hepetitio 5 Treetment Agento Gitzen and her det Hepatitis C Treatment Agents ----where increases Hepatitis C Vinus-1855A and 1853/4A The second set. 2 m m m 1 m m Human Monoclonal And Complement (CS) Inhibit Similar in the Contraction in the Hypernerice mis Tx - Unete-Oxidaxe Excyrne-Type CONTRACT MONOTONIC Stice (80, 95) Special initiality dulates 5-Lymphecyte Charmen Street and Street I manual management of the task ALC DISCOUNT OF A Continue of A Pheng: Instances ----entries and see provide a state of the second s Sage that we want to Investore appreciant - Monoclonal Ab Inhibiting T Lymph FRM I manufacture per second Affinities Chargers In such a -Like Growth Fach Neceptor (1g1-0) Induition 1.000 Integrin Receptor Antagonist, Monoclonal Antibody Let e clouid i e -d (11-d) Roc e ptor Aljohn A et agreciot, Maite Chapters et (all Porena) Letter levels = -G(1+G) Receptor Alpha Antegration, Mab E as success In the chevaletime (C. [11-6.] Place application in the Rest States in -----And the monthly the factor En aproving

DOMESTIC AND THE

Phil Providence

COR and instant

Jamus Kirsese (Jak) Inhibitory

Xel sand / Xels and XR

PaydHealth Select Drugs and Products[™] List 1/1/22 Page 3 https://www.neca-ibew.org/PaydHealth

Paydhealth

Ophthalmic Cystine Depleting: Agents Soliet Contractore The segue Collagonase Enzyme An and show Constantinoper-Lesibocyte [WBC] Stime kents Ovalizato Agent - Ovalate Inhibitor. Salarana Eta and Carlo Science -1.2.2 PRUTs Agent-Coffector OF Leakocyte Adhesion Inhib, Apha4-Neclat (gglk Nic Ab Phenylalanine Hydroxylace R L PANNE Tennenter Flangua Kallikowi w bobi hittora LHRH (GeRH) Angst PH. Sup-Central ALC: NO. NO. The second second second Circle and second Trippodur 7 olis h zymo Metabolic Dioease Encyree Replace, Hypophoophstasia Platelot Reducing Agents April 10 2.5 merceniar Pulycystic Ridowy Diseaso Agent, AVP Recept Arriag Nietabelic Dioease Encyme Repliecement, Febry's Dx T and the second second Carbon and a second at Sector and the Nexabolic Disease Encryment Replicement, Geocher's De Parlow Anto-HTN, Soluble Guanylate Cyclass Stimulator And a management Chefrone Pulce, Asti-HTM, Sel, cGIVE Second and Phosphodiocresse TS inhib Manabalic Disease Economic Planned and an oral and Person Div Pulcessary Acti-MTN, Endethelie 5 m 10 m 2 m 2 m 10 m Recognizer Ambagements Contraction and the second second Lancastron Metabolic Dx Enzyme Reple Opra w main Trans Issuer Pairsonery Antibyperturnityes, Prastacyclis-Type Printer Characterization and the Warg honory was Without a factor The second se Tyyes a pair from a Metabolic De Enzyme Replacement, Lysz, Acid Lip, Def. Liptorates i Concurre at Metabolic Dx Engrae Replacement, Sev. Comb. Immane Det. The second second Pulmonary Fibrosis - Systemic Economies Limitation and 00000 -----Retirial Enzyme Replacement Metallic Pelson, Agents to Treet 1 -----Color and in Selective Estrapers R Modulations (SER Mrs) Auchemy (all Porte al Monoclonal Antibedies Te-E-mail and a second I man a margi a b of its E [Appe] Piccillandian All states in the second second 505 - Glucagori-Like Peptide-2.)Glp 2] Analogi Monoclonal Astibody - Isterieskin S Astagosiolo Color against Sickle Cell Anemie Agents All second as Automatic Monoclonal Astibody Human Interleukin 12/23 Intel Privative at Statilization of the state attic Agennos Score aroor Public and the Part Incom Configuration (1997) -----Plance lepsy TX-H2-Recept Second compared at the statement of Low Compared Antageneiot/Inverse Agonist Spleen Tyresine Kinase Inhibiters Sector and © 2022 Paydhealth, LLC - All Rights Reserved.

Select Drugs and Products³⁴⁴ List

Effective January 1, 2022 - Healthcare practitioner-administered in Italics

Steveld Antinversionics

EMCVT: Spectra mike Exceptions instributions Amoritants AN Amoritants Amoritants And Amoritants Amoritant

IMPORTANT

This is a list of medications that changes periodically and is reviewed each calendar quarter.

To ensure you have the most current version of the Select Drugs and Products²⁴ List, visit your designated Paydhealth website address.

Inclusion of a medication on this list is not a guarantee of coverage. Please refer to your plan benefit documents for coverage limitations and exclusions.

Not all benefit plans include healthcare practitioner administered specialty drugs (noted in italics). For details regarding your benefits plan, contact Customer Service at the telephone number listed on your identification card.

Notice

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission of Paydhealth and must be used in unmodified form for information purposes only.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with Pavdhealth.

Paydhealth does not operate the websites/organizations listed here, nor is it responsible for the availability or reliability of the websites' content. These listings do not imply or constitute an endorsement, coverage, sponsorship, or recommendation by Paydhealth.

Please be advised that this document is updated periodically, and changes may appear prior to their effective date to allow for client notification.

Paydhealth

3/10/2023

PayerMatrix, Media, PA

Founded 2016

Express Scripts Pharmacy, SouthernScripts, EmiRx, Phoenix PBM, among others

YouTube: Union Labor Advisory Network interview

2021 first Innovations Summit winner at Purchasers Group on Health (WA)

Secures alternative funding

Collects commission of up to 30% of any savings

2019 New York City Transit Union vs Metropolitan Transportation Authority of NYC

 Both arguing the other brought PayerMatrix in to discussions, MTA called out union boss on "specialty drug scam" and racially discriminatory (excludes drugs for chronic diseases like sickle-cell anemia), projected savings of \$50 million, but only for US citizens, not hundreds of union members not yet citizens.

One Union Benefit Change Announcement

- Effective January 1, 2019, IPC Evergreen/PillarRx is being replaced by a new firm, Payer Matrix. Payer Matrix is able to access discounts on a larger number of specialty drugs, thereby providing more cost relief to both you and the Plan. Our goal with implementing this new vendor is that your co-pay will be entirely covered by the discount. In order to accomplish this, the new specialty drug co-payment is 100% of the discounted cost of the drug. In most case, Payer Matrix will be able to obtain alternate funding for the drug and there would be no member co-payment. If alternate funding is not available, the drug will be subject to the current tiered co-pay of \$15.00 for generic, \$45.00 for formulary brand, and \$95.00 for non-formulary brand, up to a 30-day supply.
- Effective February 1, 2019, the prescription drug formulary managed by MagellanRx will also change. Non-specialty Brand drugs not on the MagellanRx formulary will be excluded from coverage, except in circumstances of medical necessity. Medical necessity determinations including appeals will be handled by MagellanRx and their contracted independent review organizations.
- <u>https://ecommerce.issisystems.com/isite200/eremitimages/200/documents/SMM%20</u> <u>All%20Wel%20Funds%20December%202018.pdf</u>

PayerMatrix Non-Formulary Specialty Drug List 06/01/2020 Page 1

J-Code C9014	Drug Name	Alternate Funding
	BRINEURA	Alternate Funding
J0129	ORENCIA	Alternate Funding
J0135	HUMIRA	Alternate Funding
J0178	EYLEA	Alternate Funding
J0178	HARVONI	Alternate Funding
J0221	LUMIZYME	Alternate Funding
J0256	PROLASTIN	Alternate Funding
J0364	APOKYN	Alternate Funding
JD485	NUVOJIX	Limited Funding
J0490	BENLYSTA	Alternate Funding
J0517	FASENRA	Alternate Funding
J0584	CRYSVITA	Alternate Funding
J0585	BOTOX	Alternate Funding
J0588	XEOMIN	Limited Funding
J0597	BERINERT	Alternate Funding
J0599	HAEGARDA	Limited Funding
J0599	CINRYZE	Variable Funding
J0638	ILARIS	Limited Funding
J0717	CIMZIA	Alternate Funding
J0882	ARALAST	Alternate Funding
J0882	ARANESP	Alternate Funding
J0885	EPOGEN	Alternate Funding
J0885	PROCRIT	Alternate Funding
J0888	PROCRIT	Alternate Funding
J0897	PROLIA	Alternate Funding
J0897	XGEVA	Alternate Funding
J1300	SOLIRIS	Limited Funding
J1428	EXONDYS	Alternate Funding
J1438	ENBREL	Alternate Funding
J1442	NEUPOGEN	Alternate Funding
J1459	PRIVIGEN	Limited Funding
J1559	HIZENTRA	Limited Funding
J1599	TALZENNA.	Alternate Funding
J1602	SIMPONI	Alternate Funding
J1628	TREMFYA	Alternate Funding
J1645	FRAGMIN	Limited Funding
J1726	MAKENA	Alternate Funding
J1744	FIRAZYR	Variable Funding
J1745	REMICADE	Alternate Funding
J1786	CEREZYME	Variable Funding
J1830	BETASERON	Alternate Funding
J1930	SOMATULINE	Alternate Funding
J1930	SUMATULINE	Alternate Funding
J1944	ARISTADA	Alternate Funding
J2182	NUCALA	Alternate Funding
J2315	VIVITROL	Alternate Funding
J2323	TYSABRI	Alternate Funding
J2326	SPINRAZA	Alternate Funding
J2326	SPINRAZA	Variable Funding
J2350	OCREVUS	Alternate Funding
J2353	SANDOSTATIN	Alternate Funding
J2357	XOLAIR	Alternate Funding



-- Confidential --

PayerMatrix Non-Formulary Specialty Drug List 06/01/2020 Page 2

J-Code	Drug Name	Alternate Funding
J2502	SIGNIFOR	Alternate Funding
J2505	NEULASTA	Alternate Funding
J2507	KRYSTEXXA	Alternate Funding
J2786	CINQAIR	Alternate Funding
J2796	NPLATE	Limited Funding
J2840	KANUMA	Alternate Funding
J2941	GENOTROPIN	Limited Funding
J2941	HUMATROPE	Limited Funding
J2941	NORDITROPIN	Alternate Funding
J2941	NUTROPIN	Alternate Funding
J2941	OMNITROPE	Alternate Funding
J3110	FORTEO	Alternate Funding
J3111	EVENTITY	Alternate Funding
J3262	ACTEMRA	Alternate Funding
J3285	REMODULIN	Alternate Funding
J3315	TRELSTAR	Alternate Funding
J3357	STELARA	Alternate Funding
J3380	ENTYVIO	Alternate Funding
J3490	EMFLAZA.	Limited Funding
J3490	LUXTURNA.	Limited Funding
J3490	PREVYMIS	Limited Funding
J3490	TARGRETIN	Limited Funding
J3590	CABLIVI	Alternate Funding
J3590	ILUMYA.	Alternate Funding
J3590	KEVZARA	Alternate Funding
J3590	REPATHA	Alternate Funding
J3590	SILIQ	Alternate Funding
J3590	SKYRIZI	Alternate Funding
J3590	TAKHZYRO	Alternate Funding
J3590	TYMLOS	Alternate Funding
J3590	ULTOMIRIS	Variable Funding
J3590	ZOLGENSMA	Variable Funding
J3590	COSENTYX	Alternate Funding
J3950	NIMESTYM	Alternate Funding
J7170	HEMLIBRA	Limited Funding
J7179	VONVENDI	Limited Funding
J7182	NOVOEIGHT	Limited Funding
J7185	XYNTHA.	Limited Funding
J7186	ALPHANATE	Limited Funding
J7189	NOVOSEVEN	Limited Funding
J7190	HEMOFIL	Limited Funding
J7192	ADVATE	Limited Funding
J7192	KOGENATE	Limited Funding
J7192	RECOMBINATE	Limited Funding
J7193	ALPHANINE	Alternate Funding
J7193	MONONINE	Limited Funding
J7195	BENEFIX	Limited Funding
J7195	DXINITY	Limited Funding
J7198	FEIBA.	Limited Funding
J7200	RIXUBIS	Limited Funding
J7201	ALPROLIX	Limited Funding
J7202	IDELVION	Limited Funding



-- Confidential --

PaverMatrix Non-Formularv Specialtv Drug List 06/01/2020 Page 3

J-Code	Drug Name	Alternate Funding
J7207	ADYNOVATE	Limited Funding
J7208	JIM	Limited Funding
J7209	NUWIQ	Alternate Funding
J7210	AFSTYLA	Limited Funding
J7211	KOVALTRY	Limited Funding
J7312	OZURDEX	Alternate Funding
J7313	ILUVIEN	Alternate Funding
J7502	SANDIMMUNE	Alternate Funding
J8499	EPIDIOLEX	Limited Funding
J8499	GALAFOLD	Variable Funding
J8655	AKYNZEO	Alternate Funding
J8655	DOVATO	Alternate Funding
J8999	COTELLIC	Alternate Funding
J8999	DAURISMO	Alternate Funding
J8999	ERIVEDGE	Alternate Funding
J8999	IBRANCE	Alternate Funding
J8999	NEXAVAR	Alternate Funding
J8999	RUBRACA	Limited Funding
J8999	TARCEVA	Limited Funding
J8999	TIBSOVO	Limited Funding
J8999	XOSPATA	Limited Funding
J8999	ZOLINZA	Alternate Funding
J9022	TECENTRIQ	Variable Funding
J9035	AVASTIN	Limited Funding
J9041	VELCADE	Alternate Funding
J9119	LIBTAYO	Limited Funding
J9145	DARZALEX	Alternate Funding
J9176	EMPLICITI	Limited Funding
J9202	ZOLADEX	Limited Funding
J9228	YERVOY	Alternate Funding
J9264	ABRAXANE	Alternate Funding
J9271	KEYTRUDA	Alternate Funding
J9299	OPDIVO	Alternate Funding
J9303	VECTIBIX	Alternate Funding
J9306	PERJETA	Alternate Funding
J9312	RITUXAN	Alternate Funding
J9325	IMLYGIC	Alternate Funding
J9330	TORISEL	Alternate Funding
J9355	HERCEPTIN	Alternate Funding
J9400	ZALTRAP	Limited Funding
Q2040	KYMRIAH	Alternate Funding
Q2041	YESCARTA	Alternate Funding
Q5104	RENFLEXIS	Alternate Funding
Q5105	RETACRIT	Alternate Funding



-- Confidential --

RxFree4Me, Detroit, MI area

Save up to 75% of cost of medications.

Drugs dispensed domestically and from Canada

Savings becomes a \$0 copay to employees

Patient holds the prescription from the MD and passes it on for filling

Terms and Conditions reference shipping delays, delivery must be signed for, "prescription has not been altered in any way nor has it been filled prior to submission to RxFree4Me", patient must contact physician if they have any unexpected side effects from medications ordered from RxFree4Me

SHARx, St. Louis, MO

Targets all high cost medications that are driving up employer health care costs

Members often get their drugs free, and those that are not free are typically at cash pharmacies with pricing 75% to 90% lower than local pharmacies

CEO had child with rare disease and found resource that paid for all of the financial costs...so founded SHARx

Works with multiple PBMs, fulfills prescriptions through non-traditional channels

Fee paid per employee per month

Procures high cost maintenance, specialty meds, infusion therapies, and orphan disease drugs directly from the manufacturer or through mail order pharmacy partners (i.e. Humira, Cosentryx, or Spinraza)

Lots of YouTube videos at <u>https://www.sharxplan.com/group-faqs/</u>

Caution: medications can take 2 to 4 weeks or 5 to 7 weeks depending on whether they are shipped domestically, from Canada, or from overseas

What does SHARx call High Cost Drugs?

• Any medication that costs **more than \$200 for a 30-day supply** would be considered high-cost. These would include: Insulin (all types), Abilify, Actemra, Advair, Androgrel, Atripla, Breo, Brilinta, budesonide, Bydureon, Canasa, Celebrex, Cialis, Concerta, Crestor, Cymbalta, Dexilant, Effient, Eliquis, Elmiron, Enbrel, Flovent HFA, Gilenya, Glatopa, Glyxambi, Humira, Invokana, Janumet, Januvia, Latuda, Lipitor, Lyrica, Multaq, Onfi, Plavix, Premarin, Prolia, Remicade, Restasis, Seroquel, Singulair, Spiriva, Stelara, Toujeo, Viagra, Victoza, Vyvanse, Welchol, Xaralto, Xolair, and MANY, MANY More!!

SHARx Results

Large Employers

- 2077 lives, \$4.2 million savings
- 1,260 lives, \$1.3 million savings

Mid Size Employers

- 237 lives, \$238K savings
- 157 lives, \$227K savings

Average Employer savings is \$1,100 per enrolled employee. Average employee savings is \$800

ScriptSourcing, Bonita Springs, FL, Baltimore, MD

Search function for medications they can source

Enroll in \$0 Rx copay programs

Rather than use PBM, use ScriptSourcing to **direct source specialty medications** at typical savings of 50 - 75%

Paid on % of savings

Home Health care client in PA with 130 enrolled members saved \$608K in 4 years. Refills mailed direct to member homes, 85% first year savings

Manufacturer client in CA with 350 employees. Within 4 months, 42 prescriptions saved \$192K. 67% savings and members had \$0 copay

Private college in PA with 721 enrolled members. Within 6 months, \$120K savings. By end of year, \$177K savings. Members had \$0 copay

SaveOnSP, New York State

- SaveOnSP is marketed by Express Scripts and Express Scripts is now a CIGNA company
- "non-essential health benefits copay assistance solution"
- Identifies select drugs as non-essential health benefits, so they can be carved out, enabling maximum savings and reducing plan and member costs. The Affordable Care Act (ACA) Essential Health Benefit requirements don't cover drugs declared to be "nonessential health benefits", so those drugs can be carved out of a health benefit plan.
- If patients needing those carved out drugs do not enroll in and use SaveOnSP, filling their prescriptions exclusively from Express Script's Accredo SP, they can require patients to pay the full amount of the value of the manufacturer's copayment program. If a copayment program value is \$20,000, not enrolling in SaveOnSP could cost a patient the full \$20,000 without regard to plan OOP maximums.
- Elements of a copay maximizer program when patient out of pocket drug costs are \$0, patients still owe their full deductible for other expenses
- Receives 25% of savings as a fee
- Founded in 2015

Lawsuit against SaveOnSP

Brought by Johnson & Johnson in 2022 in New Jersey

SaveOnSP has moved to dismiss

Aimed Alliance, Triage Cancer, the HIV and Hepatitis Policy Institute, The Coalition of State Rhematology Organizations, and the AIDS Institute, the National Oncology State Network and the Connecticut Oncology Association have filed an Amici Curiae Brief August 15, 2022 in opposition to SaveOnSP's motion to dismiss. <u>https://aimedalliance.org/aimed-alliance-submits-amicus-brief-in-lawsuit-to-enjoin-non-ehb-program/</u>

<u>https://endpts.com/jj-suing-company-over-alleged-abuse-of-its-cost-assistance-program/</u>

Adverse Consequences: Real and Potential

Growing Awareness

- Treating Providers in Oncology and Other Specialties Rheumatology, Cardiology, Infectious Disease, etc.
- Affected Patients/Employees
- Patient Assistance Programs, Charities, Foundations
- Pharma

View from Rheumatology

- For employers, the cost of health insurance is second only to their payroll expense. Per person spending in employer plans grew by 22% between 2015 and 2019. This outpaced inflation and economic growth.
- Because employers who self-fund the health care for their employees are increasingly desperate to save money, they will often agree to plans that are less expensive but offer suboptimal care, particularly for patients with chronic diseases requiring expensive medicines.
- Many employers are not fully informed of the ramifications of these policies, so the Coalition of State Rheumatology Organizations is creating an educational employer tool kit that not only highlights the importance of disease control for their employees with rheumatic conditions but also outlines the pitfalls and misinformation that may be given to them by the insurance companies, PBMs, and other third parties that administer their health plan.
- Utilization management legislation, which has passed in many states, can be easily found on CSRO's map tool https://csro.info/non_cms_pages/legislationin-your-state.php

Forced 'white bagging' in self-funded plans

- TPAs then attempt to obtain the medications from the manufacturers, foundations, compounding pharmacies, and even other countries for free or highly discounted prices. Even if obtained at no cost, the TPA will charge the employer a percentage of the list price or fee for obtaining it.
- The legality of this practice is questionable when these companies pretend to be the patient when applying for the assistance or present compounded medication as coming from the manufacturer, or if the TPA obtains the medication from outside the country.

 "Employers' self-funded health plans can leave rheumatology patients vulnerable", Madelaine Feldman, MD, MD edge Rheumatology, September 20, 2022

Messaging is a Challenge

- Talking to those thinking this is a good program
- Threatening what some will perceive as a fair use of alternative funding to combat high costs of health care for vulnerable employers/unions, etc.
- Raising adverse consequences that may not be a concern to the beholder
- Federal and state agencies may be affected
- Insurance commissions and state consumer advocacy may be concerned

Good or Bad is a Point of View

Employer/Employee

- Specialty funding available for the seeking
- \$0 drug cost to employer for high-cost specialty/orphan drugs
- \$0 copays
- Willing to pay 25- 30% to get hundreds of thousands or millions in savings
- Presented at "Best of the Best' employer business group meetings for innovation
- Savings from shipped drugs from Canada and overseas is an asset (50% 75%)
- Blind eye being turned to importation due to savings potential (municipalities, states, employers)

Physician/Manufacturer/Foundations/C APs

- Specialty funding is limited and reserved for patients in need
- Employers making a financial decision to carve out specific drugs and diseases based upon cost does not constitute the definition of patients in need
- Draining "soup kitchens" equivalent
- Importation of drugs from Canada or overseas for quantities greater than individual use is against federal law
- Physicians still held liable for medical complications even if they have no control over sourcing of drug

Legal Challenges?

Patient Harm

- Direct from unpedigreed drugs
- Indirect by reduced access to needed drugs because programs were drained

Treatment Delays

Confusion

Coercion to enroll

Risk/Harm/Legality of Drug Importation

Amici Curiai Brief

Amici Curiae Brief August 15, 2022 in opposition to SaveOnSP's motion to dismiss, on grounds that SaveonSP:

- Conduct deceives, influences, and harms consumers
- Conduct deceives health care consumers
 - Causes pharmacies to tell consumers that their medications are not covered by insurance
 - Informs consumers that, under its program, there is no copay
 - Does not disclose that, under its program, copay assistance is not counted toward consumers' deductible or annual out-of-pocket limit
 - Does not disclose that it places its interests before the interests of consumers
- Conduct harms consumers
 - Conduct delays health care access and causes consumers to pay more for their health care
 - Conduct causes consumers to forego health care products and services
- Conduct has national health policy implications
 - Mischaracterizes the purposes of Copay Assistance Programs (CAPS)
 - Threatens patient's health stability by jeopardizing their ability to rely on CAPS
 - Threatens patient and public health by serving as a roadmap for eroding Employee Health Benefit (EHB) protections
 - Increases overall health care costs by inflating the cost of prescription medications
- <u>https://aimedalliance.org/aimed-alliance-submits-amicus-brief-in-lawsuit-to-enjoin-non-ehb-program/</u>

Plan of Action for Change

Awareness, Document, Education, Challenge

Awareness

- Watch for specialty carveouts for employed patients
- Track employer for all patients to facilitate trend analysis

Document

- Document disease, drugs, employers
- Document adverse consequences for patients as they are forced through the process, rates of substitution, funding sources, medication sources, frequency of recoverage under benefit plan if patient not eligible, frequency of patient forgoing needed treatment due to the process or communications, track communications regarding the program sent to prescribing physicians, track impact on patients if physicians refuses whitebagged drugs

Education

• Align with state societies, National Oncology State Network, Aimed Alliance and others to develop talking points, key issues, to be shared with employers of affected employees: unanticipated adverse consequences, legal and risk challenges, safety concerns, continuity of care issues, etc.

Challenge

• Serve as an ambassador to local business groups, unions, employee groups, accountable care organizations, individual employers, to warn of the adverse consequences to benefit members, employers, patients in need, foundations, CAPS, and oncology providers from these programs

If we see something, say something

These are not specialty funding sources with pots of free money for the taking

They are raised funds designated for patients in need

Selectively un-insuring employed insured patients for specific diseases, orphan diseases, solely based upon the costs of treatment is reprehensible, but may be naïve

Third parties engaged in these "sales" to employers are not telling them the whole story. Employers also are being tempted and deceived by these entities and deserve to know the full implications.

Importation of drugs for vulnerable patients is illegal on a wholesale basis, dangerous, inadequately monitored, and unsafe

We cannot be Naïve either

Medical and pharmaceutical costs are sky-high

For any employer, less than 5% of their insured members could incur unsustainable cost burdens.

1.2% of insured members can be responsible for 1/3 of employer medical costs

Programs that shift savings into \$0 member out of pocket costs may increase compliance and adherence

What would you do as an employer if these companies pitched these savings for your own benefit plan?

What is the tipping point for penetration of these programs to drain specialty funding sources? When or can we document needy patients being harmed or losing access to care? Countering such programs must be grounded in facts, not emotions.

Become Vocal

- Join National Oncology State Network (NOSN) in awareness, tracking, and addressing on a state and national basis
- Start tracking incidence, employers, vendors in your own area
- Check your own organization health benefits structures to see if these programs are contracted
- Use NOSN resources and reach out to local employers and state legislators advocacy, and regulatory agencies
- Engage your own patient resources, charities, foundations, to collaborate on identification and approach.
- Use me as an ally and resource

Resources

- Oncology Practice Management
 - Specialty Carveout Models Cost Patients and Employers More Than They Disclose

https://oncpracticemanagement.com/issues/2023/february-2023-vol-13-no-2/3133-specialty-carve-out-models-costpatients-and-employers-more-than-they-disclose

• Specialty Carve-Outs: What Are the Implications for Patients and Practices?

https://oncpracticemanagement.com/issues/2022/december-2022-vol-12-no-12/3013-specialty-carve-outs-what-are-theimplications-for-patients-and-practices Thank You, and Good Luck Dawn Holcombe, MBA, FACMPE DGH Consulting 33 Woodmar Circle South Windsor, CT 06074

860-305-4510 <u>dawnho@aol.com</u> www.dghconsulting.net